Table 3.
Follow-up period, number of events and incidence per 1000 person years
| Event | Lispro (n = 14,047) | Aspart (n = 26,813) | Glulisine (n = 305) |
|---|---|---|---|
| Deaths | 563 (6.2) | 1223 (7.9) | 6 (7.7) |
| Fatal CHD | 198 (2.2) | 444 (2.9) | 0 (0.0) |
| Fatal CVD | 225 (2.5) | 505 (3.2) | 0 (0.0) |
| CHD | 898 (10.3) | 1676 (11.1) | 9 (11.7) |
| CVD | 1283 (14.9) | 2352 (15.9) | 13 (17) |
| Stroke | 285 (3.2) | 441 (2.9) | 2 (2.6) |
| Heart failure | 374 (4.2) | 743 (4.8) | 3 (3.9) |
| Kidney failure | 385 (4.3) | 724 (4.7) | 3 (3.9) |
| Hypoglycemia | 706 (8.0) | 1299 (8.6) | 3 (3.9) |
| Hyperglycemia | 929 (10.7) | 1946 (13.0) | 3 (3.9) |
| Maximum follow-up time, years | 7.5 | 7.5 | 7 |
| Mean follow-up time, years | 6.4 | 5.8 | 2.5 |
| Median follow-up time, years | 6.8 | 6.6 | 2.7 |
Values are presented as number of events (incidence per 1000 person-years) unless otherwise stated
CHD coronary heart disease, CVD cardiovascular disease